SANES

10.804

+1.54%↑

BBVA

19.59

-0.05%↓

BNP

94.3

+0.89%↑

CABK

11.56

+0.87%↑

INGA

26.335

+0.57%↑

SANES

10.804

+1.54%↑

BBVA

19.59

-0.05%↓

BNP

94.3

+0.89%↑

CABK

11.56

+0.87%↑

INGA

26.335

+0.57%↑

SANES

10.804

+1.54%↑

BBVA

19.59

-0.05%↓

BNP

94.3

+0.89%↑

CABK

11.56

+0.87%↑

INGA

26.335

+0.57%↑

SANES

10.804

+1.54%↑

BBVA

19.59

-0.05%↓

BNP

94.3

+0.89%↑

CABK

11.56

+0.87%↑

INGA

26.335

+0.57%↑

SANES

10.804

+1.54%↑

BBVA

19.59

-0.05%↓

BNP

94.3

+0.89%↑

CABK

11.56

+0.87%↑

INGA

26.335

+0.57%↑

Home・Aandelen Lijst・Bayer AG

Bayer AG

Open

SectorFinanciën

36.08 2.79

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

35.12

Max

36.1

Belangrijke statistieken
By Trading Economics
Inkomsten	6.5B 2.8B
Verkoop	2B 13B
EPS	2.812
Dividendrendement	0.3
Winstmarge	20.612
Werknemers	87,757
EBITDA	2.3B 4.4B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+42.01% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	0.30% 4.65%
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.9B 35B
Vorige openingsprijs	33.29
Vorige sluitingsprijs	36.08

Nieuwssentiment

By Acuity

29%

71%

57 / 439 Rangschikking in Finance

Bayer AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 jun 2026, 11:21 UTC

Belangrijke Marktbewegers

Bayer Shares Fall on Renewed Uncertainty Over $7 Billion U.S. Settlement

12 mei 2026, 11:24 UTC

Winsten

Belangrijke Marktbewegers

Bayer Shares Climb After Earnings Beat Expectations

12 mei 2026, 06:10 UTC

Winsten

Bayer Net Profit Surges Driven by Growth in Agricultural Division

6 mei 2026, 10:51 UTC

Acquisities, Fusies, Overnames

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6 mei 2026, 07:01 UTC

Acquisities, Fusies, Overnames

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

2 jun 2026, 11:22 UTC

Marktinformatie

Bayer Hit by New Roundup Legal Jitters -- Market Talk

29 mei 2026, 08:15 UTC

Marktinformatie

Winsten

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

29 mei 2026, 07:42 UTC

Marktinformatie

Bayer Can Still Take Hit if Litigation Strategy Fails -- Market Talk

12 mei 2026, 12:05 UTC

Populaire aandelen

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 mei 2026, 10:51 UTC

Populaire aandelen

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 mei 2026, 09:08 UTC

Populaire aandelen

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

12 mei 2026, 05:38 UTC

Winsten

Bayer Backs 2026 Outlook Adjusted for Currency

12 mei 2026, 05:36 UTC

Winsten

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

12 mei 2026, 05:36 UTC

Winsten

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

12 mei 2026, 05:36 UTC

Winsten

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

12 mei 2026, 05:35 UTC

Winsten

Bayer 1Q Adj EPS EUR2.71

12 mei 2026, 05:34 UTC

Winsten

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

12 mei 2026, 05:34 UTC

Winsten

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

12 mei 2026, 05:34 UTC

Winsten

Analysts Saw Bayer 1Q Sales at EUR13.42B

12 mei 2026, 05:34 UTC

Winsten

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

12 mei 2026, 05:33 UTC

Winsten

Bayer 1Q EBIT EUR3.53B

12 mei 2026, 05:32 UTC

Winsten

Bayer 1Q Ebitda Before Special Items EUR4.45B

12 mei 2026, 05:32 UTC

Winsten

Bayer 1Q Net Pft EUR2.76B

12 mei 2026, 05:31 UTC

Winsten

Bayer 1Q Sales EUR13.405B

12 mei 2026, 05:31 UTC

Winsten

Bayer Backs 2026 View

6 mei 2026, 06:34 UTC

Acquisities, Fusies, Overnames

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6 mei 2026, 06:33 UTC

Acquisities, Fusies, Overnames

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6 mei 2026, 06:33 UTC

Acquisities, Fusies, Overnames

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6 mei 2026, 06:32 UTC

Acquisities, Fusies, Overnames

Bayer to Pay $300M Upfront

6 mei 2026, 06:32 UTC

Acquisities, Fusies, Overnames

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

Peer Vergelijking

Prijswijziging

Bayer AG Prognose

Koersdoel

By TipRanks

42.01% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 50.5 EUR 42.01%

Hoogste 56 EUR

Laagste 40 EUR

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bayer AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Bayer AG - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

57 / 439 Rangschikking in Financiën

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.